Drugs / CD8-positive WT1 gene-specific CTL clones
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00052520 | Sep 2002 → Apr 2011 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +11 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD8-positive WT1 gene-specific CTL clones | “Donors undergo leukapheresis for stem cell harvest to generate CD8-positive WT1 gene-specific CTL clones at the time of allogeneic stem cell transplantation.” NCT00052520 ↗ |
| Action | Deplete | “Immunotherapy given to patients who have undergone donor stem cell transplantation may be a way to eradicate remaining cancer cells” NCT00052520 ↗ |
| Modality | Cell therapy | “adoptive immunotherapy with CD8+ WT1-Specific CTL Clones” NCT00052520 ↗ |
| Route | Intravenous | “CD8-positive WT1 gene-specific CTL clones intravenously (IV)” NCT00052520 ↗ |
| Target | WT1 | “CD8-positive WT1 gene-specific CTL clones” NCT00052520 ↗ |